Footrot vaccine closer than ever

Jul 02, 2008

Monash University scientists have started clinical trials to find a successful vaccine against footrot in sheep.

The trials have been made possible with funding of $663,000 from Australian Wool Innovation (AWI).

The trials over three years are taking place at Monash University's Australian Research Council Centre of Excellence in Structural and Functional Microbial Genomics and the University of Sydney.

Chief investigator Professor Julian Rood said it was an exciting development for his team of researchers.

"The trials are the culmination of 8 years of collaborative work on the pathogenic bacterium which causes footrot, Dichelobacter nodosus. We have determined the bacterium's complete DNA sequence, which was then analysed to identify proteins that are potentially exposed on the surface of the causative bacterium and therefore more likely to elicit an immune response," Professor Rood said.

"The approach, called reverse vaccinology, identified 90 proteins in the footrot bacterium that are potential antigens for a new cross-protective vaccine. This funding will allow us to pinpoint those proteins that will target the disease in a vaccine application," Professor Rood said.

"Our Centre's approach has made significant inroads in the development of a novel vaccine for footrot. The trialling process involves treating sheep with purified surface expressed proteins to assess whether they produce an immune response. The AWI funding means the development of a marketable vaccine is likely to happen a lot sooner. Ideally, this could be within a decade."

Australian Wool Innovation's Program Manager of Animal Health, Productivity and Welfare, Dr Johann Schröder said footrot has long been the bane of Australian woolgrowers and prime lamb producers.

"While many improvements have been made over the years in its control, and we have a very good understanding of measures to limit its impact on production, this avenue of research holds great promise," Dr Schröder said.

Source: Monash University

Explore further: Booming mobile health app market needs more FDA oversight for consumer safety, confidence

add to favorites email to friend print save as pdf

Related Stories

Scalping can raise ticket prices

3 hours ago

Scalping gets a bad rap. For years, artists and concert promoters have stigmatized ticket resale as a practice that unfairly hurts their own sales and forces fans to pay exorbitant prices for tickets to sold-out concerts. ...

Tropical Storm Genevieve forms in Eastern Pacific

5 hours ago

The seventh tropical depression of the Eastern Pacific Ocean formed and quickly ramped up to a tropical storm named "Genevieve." NOAA's GOES-West satellite captured an infrared image of the newborn storm ...

Recommended for you

Determine patient preferences by means of conjoint analysis

9 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments : 0